Peptide library / Immune & defense / Dalbavancin
Dalbavancin
A long-acting lipoglycopeptide antibiotic given as one or two infusions.
Effects studied or claimed
What it is used or promoted for, and where each effect has actually been seen
- Acute bacterial skin infectionsFDA approved
- Bone and joint infection, off-labelSmall human studies
How it is thought to work
Dalbavancin blocks cell wall synthesis in Gram-positive bacteria and its long half-life allows weekly dosing.
What the evidence shows
Trials showed a single dose was non-inferior to a longer course of other antibiotics for skin infection.
Safety and unknowns
Nausea, headache and diarrhea are the most frequent.
Regulatory status
FDA-approved as Dalvance in 2014.
Regulatory status changes quickly. This entry was last reviewed on 27 October 2026. Confirm current status with the FDA before relying on it.
More in Immune & defense
Daptomycin
FDA-approvedA cyclic lipopeptide antibiotic from soil bacteria for serious skin and bloodstream infections.
Echinocandins
FDA-approvedA class of cyclic lipopeptide antifungals and first-line treatment for invasive Candida infections.
Cyclosporine
FDA-approvedAn 11 amino acid cyclic peptide from a soil fungus that made organ transplantation routine.
General information, not medical advice. Do not buy or inject unregulated peptides.